SEC filings
Johnson & Johnson (JNJ)
Recent filings Johnson & Johnson made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000200406All filings on SEC.gov
10-QQuarterly report
Quarterly report
Johnson & Johnson reported worldwide sales of $74.8 billion for the first nine months of fiscal 2026, a 7.4% increase from a year earlier, and third-quarter sales of $25.4 billion, up 5.9%. …
8-KCurrent report
Results of Operations and Financial Condition
Johnson & Johnson reported third-quarter 2026 sales growth of 5.9% to $25.4 billion and raised its full-year 2026 guidance to estimated reported sales of $101.2 billion and adjusted EPS of $11.10, while diluted EPS fell to $0.09 on a…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine effective September 1, 2026, and that Tom Cavanaugh, currently Company Group Chairman, North America…
8-KCurrent report
Regulation FD Disclosure
Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, Inc., whose Firelink degrader antibody conjugate platform targets pan-KRAS and other drivers of hard-to-treat solid tumors, and entered strategic agreements and a…
8-KCurrent report
Regulation FD Disclosure
Johnson & Johnson announced a proposed comprehensive resolution of the remaining ovarian talc litigation with plaintiff firms leading the federal Multi-District Litigation and related state court proceedings, conditioned on participation…
10-QQuarterly report
Quarterly report
Johnson & Johnson reported fiscal first-half 2026 worldwide sales of $49.4 billion, up 8.2% from a year earlier, and fiscal second-quarter sales of $25.3 billion, up 6.6%, with biosimilar competition for STELARA cutting operational sales…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Johnson & Johnson in Readster
Add Johnson & Johnson to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.